Kelly HA, Chikandiwa A, Sawadogo B, et al. - Risk of cervical cancer and precancer is reported to be high among women living with human immunodeficiency virus (WLHIV). Researchers aimed at examining the sensitivity, specificity, and positive predictive value of different cervical cancer strategies in WLHIV in Africa. In this prospective study of over 1,200 WLHIV in sub-Saharan Africa, they evaluated visual inspection using acetic acid (VIA) or visual inspection using Lugol’s iodine (VILI), high-risk human papillomavirus DNA test (Hybrid Capture 2 [HC2] or careHPV), and cytology for histology-verified high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) at baseline and endline, a median 16 months later. Per findings, an HPV DNA test seemed to identify a greater number of women with precancer compared with visual inspection and cytology methods. However, a greater proportion of women were also identified who were without precancer and had a positive HPV DNA test, indicating the necessity for a triage test using cytology or visual inspection to determine treatment eligibility. Fewer women without precancer testing positive and fewer women needing triage were identified following simple user-applied modifications to the HPV-DNA-based test. Findings suggest cervical cytology to be a valuable triage test for HPV-positive women in settings with adequate infrastructure.